A medical company is due to relocate to south Wales after securing £33.2m to continue its research into stem cells which can repair damaged tissue. ReNeuron has received almost £14m in Welsh government grants and investments as part of its move from Guilford.
Minister Edwina Hart said life sciences was a key business sector with the “potential to make a significant contribution to the Welsh economy”.
The company is working on treatment for stroke patients.
Bosses are planning to relocate to south Wales over the next two years, bringing 25 jobs and possibly expanding to employ about 70 people. It has not been established exactly where the company will be based.
The deal includes £7.8m of Welsh government grants and £5m equity investment from Wales Life Sciences Investment Fund which is worth £100m.
‘Exciting and innovative’
The Welsh government says life sciences – which includes pharmaceutical and medical technology firms – employs 15,000 people in Wales and is worth £1.3bn to the economy.
Ministers have previously spoken about their desire to make Wales an attractive place for scientific research and development.
Arthurian Life Sciences Limited manages the investment fund and its chairman Prof Sir Chris Evans is said to have devised the plan leading to ReNeuron’s move.
“This transaction represents the sort of exciting and innovative deal and investment that will become the hallmark of this Arthurian investment strategy for Wales,” said Prof Evans, who is originally from Port Talbot.
He is a scientist and entrepreneur who has created over 50 medical companies with some since sold as multi-million pound enterprises.
Ms Hart, Minister for Business, Economy, Transport and Science, said she was “delighted” by ReNeuron plans.
“ReNeuron is the first company in the world to have been granted permission to run clinical trials of ground-breaking stem cell technology to treat patients with stroke, one of the top three causes of death and a leading cause of adult disability in Wales,” she said.